Azilsartan medoxomil (Edarbi) the eighth ARB.

Found an issue? Give us feedback

The Medical Letter o...arrow_drop_down

The Medical Letter on Drugs and Therapeutics

Article . 2011

Data sources: Europe PubMed Central

Azilsartan medoxomil (Edarbi) the eighth ARB.

descriptionPublicationkeyboard_double_arrow_right Article 19 Jul 2011 English Journal:The Medical letter on drugs and therapeutics, volume 53 (issn: 1523-2859,

Copyright policy )

pmid: 21566544

Azilsartan medoxomil (Edarbi) the eighth ARB.

- Summary
- Subjects
- Metrics

Abstract

The angiotensin receptor blocker (ARB) azilsartan medoxomil (Edarbi-Takeda) was recently approved by the FDA for oral treatment of hypertension, either alone or combined with other drugs. It is the eighth ARB approved for this indication.

Keywords

Angiotensin Receptor Antagonists, Oxadiazoles, Hypertension, Humans, Benzimidazoles, Blood Pressure, Receptor, Angiotensin, Type 1, Randomized Controlled Trials as Topic

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	2
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average